Sironax Phase 2 trial reaches half enrollment for SIR4156 obesity study
Sironax said on 13 October that it has reached about 50 percent of its targeted patient enrollment in its global Phase 2 FORGE-LM trial of SIR4156, an orally active allosteric NAMPT activator being evaluated in combination with semaglutide in adults with obesity. The double-blind, randomized, placeb
<p>Sironax said on 13 October that it has reached about 50 percent of its targeted patient enrollment in its global Phase 2 FORGE-LM trial of SIR4156, an orally active allosteric NAMPT activator being evaluated in combination with semaglutide in adults with obesity. The double-blind, randomized, placeb</p>